ChemoMetec A/S (CHEMM) - Total Assets
Based on the latest financial reports, ChemoMetec A/S (CHEMM) holds total assets worth Dkr783.37 Million DKK (≈ $122.56 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ChemoMetec A/S cash conversion from operations for how efficiently the company converts equity into cash flow.
ChemoMetec A/S - Total Assets Trend (2004–2025)
This chart illustrates how ChemoMetec A/S's total assets have evolved over time, based on quarterly financial data. See CHEMM stock price for real-time trading data and today's change.
ChemoMetec A/S - Asset Composition Analysis
Current Asset Composition (June 2025)
ChemoMetec A/S's total assets of Dkr783.37 Million consist of 65.6% current assets and 34.4% non-current assets. Explore CHEMM current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 41.3% |
| Accounts Receivable | Dkr79.62 Million | 9.6% |
| Inventory | Dkr109.34 Million | 13.2% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr145.69 Million | 17.6% |
| Goodwill | Dkr7.35 Million | 0.9% |
Asset Composition Trend (2004–2025)
This chart illustrates how ChemoMetec A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ChemoMetec A/S's current assets represent 65.6% of total assets in 2025, an increase from 52.7% in 2004.
- Cash Position: Cash and equivalents constituted 41.3% of total assets in 2025, up from 5.1% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 10.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 17.6% of total assets.
ChemoMetec A/S Competitors by Total Assets
Key competitors of ChemoMetec A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
MicroPort Endovascular MedTech Ltd
SHG:688016
|
China | CN¥4.96 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
DRTECH Corporation
KQ:214680
|
Korea | ₩235.84 Billion |
ChemoMetec A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.93 | 4.00 | 4.15 |
| Quick Ratio | 3.06 | 2.92 | 3.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr361.17 Million | Dkr368.22 Million | Dkr143.73 Million |
ChemoMetec A/S - Advanced Valuation Insights
This section examines the relationship between ChemoMetec A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.44 |
| Latest Market Cap to Assets Ratio | 1.83 |
| Asset Growth Rate (YoY) | 22.4% |
| Total Assets | Dkr828.05 Million |
| Market Capitalization | $1.51 Billion USD |
Valuation Analysis
Above Book Valuation: The market values ChemoMetec A/S's assets above their book value (1.83x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: ChemoMetec A/S's assets grew by 22.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ChemoMetec A/S (2004–2025)
The table below shows the annual total assets of ChemoMetec A/S from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | Dkr828.05 Million ≈ $129.55 Million |
+22.37% |
| 2024-06-30 | Dkr676.67 Million ≈ $105.87 Million |
+2.84% |
| 2023-06-30 | Dkr657.98 Million ≈ $102.95 Million |
+31.26% |
| 2022-06-30 | Dkr501.27 Million ≈ $78.43 Million |
+45.33% |
| 2021-06-30 | Dkr344.91 Million ≈ $53.96 Million |
+31.09% |
| 2020-06-30 | Dkr263.12 Million ≈ $41.17 Million |
+10.45% |
| 2019-06-30 | Dkr238.22 Million ≈ $37.27 Million |
+108.97% |
| 2018-06-30 | Dkr114.00 Million ≈ $17.84 Million |
+16.77% |
| 2017-06-30 | Dkr97.62 Million ≈ $15.27 Million |
+8.01% |
| 2016-06-30 | Dkr90.38 Million ≈ $14.14 Million |
+42.41% |
| 2015-06-30 | Dkr63.47 Million ≈ $9.93 Million |
+23.59% |
| 2014-06-30 | Dkr51.35 Million ≈ $8.03 Million |
+1.07% |
| 2013-06-30 | Dkr50.80 Million ≈ $7.95 Million |
+1.83% |
| 2012-06-30 | Dkr49.89 Million ≈ $7.81 Million |
-17.91% |
| 2011-06-30 | Dkr60.78 Million ≈ $9.51 Million |
-3.09% |
| 2010-06-30 | Dkr62.72 Million ≈ $9.81 Million |
-3.76% |
| 2009-06-30 | Dkr65.16 Million ≈ $10.20 Million |
+16.25% |
| 2008-06-30 | Dkr56.05 Million ≈ $8.77 Million |
+8.88% |
| 2007-06-30 | Dkr51.48 Million ≈ $8.05 Million |
+60.76% |
| 2006-06-30 | Dkr32.02 Million ≈ $5.01 Million |
+304.59% |
| 2005-06-30 | Dkr7.92 Million ≈ $1.24 Million |
+52.48% |
| 2004-06-30 | Dkr5.19 Million ≈ $812.17K |
-- |
About ChemoMetec A/S
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, an… Read more